Compass Pathways, a leading developer of psilocybin-based therapies, has announced significant delays for its two key Phase 3 clinical trials. These delays, attributed to unexpected complexities in trial logistics and a need to maintain trial blinding integrity, have led to a 30% workforce reduction, including senior management roles. The company remains committed to its COMP360 program for treatment-resistant depression, focusing resources on completing trials and navigating regulatory processes.